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Front cover 
Scanning electron microscopic picture of a prostate adenocarcinoma cell (PC-3), after 
migration through a reconstituted basal lamina (Matrigel ®). The cell has moved 
through the pore shown to the right. Before migration, the cell must have been 
capable of degrading and destroying the Matrigel® protein matrix which covered the 
pore. Conditioned medium from a mouse fibroblast cell line (NIH-3T3) was used as 
chemo-attractant. The specimen was prefixed in glutaraldehyde, postfixed in 
osmiumtetroxid, critical-point dried and stained with gold-palladium. 
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Abbreviations 
uPA          urokinase plasminogen activator 
uPAR       urokinase plasminogen activator receptor 
MMP       matrix metalloproteinase  
TKI          tyrosine kinase inhibitor 
BL           basal lamina 
ECM        extracellular matrix 
TIMP       tissue inhibitor of metalloproteinase 
PAI          plasminogen activator inhibitor 
EGF         epidermal growth factor 
EGFR      epidermal growth factor receptor 
GPI          glycosyl phosphatidylinositol 
PSA          prostate specific antigen 
HRPCA    hormone refractory prostate cancer      
TK(R)       tyrosine kinase (receptor) 
TGF          transforming growth factor 
HER-2      human epidermal growth factor receptor 2 
SH2/3       Rous’ sarcoma virus homology 2 and 3  
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Introduction 
Prostate cancer: the clinical and scientific challenge 
Prostate carcinoma is the most frequent cancer among men in Norway with 3327 new 
cases in 2003 [1], and it is a leading cause of cancer deaths in men. More than any 
other, prostatic cancer is a disease of the elderly. In fact in developed countries 82 % 
of cases occur in men older than 65 years [2]. An expected increase of longevity will 
probably result in 40 % more prostate cancer cases in the future [3]. However, the 
patient cohort is heterogeneous especially regarding progression of the disease. In 
most patients the cancer remains slow-growing, but in a minority of cases the tumor is 
highly aggressive, leading to early metastasis with painful bone lesions, and 
unfortunately to death in the course of a few years [4]. An important challenge for the 
future will be to find a diagnostic method that can reliably identify such aggressive 
cases. 
Treatment options and shortcomings of existing therapy 
Asymptomatic prostate cancer is usually discovered by high levels of prostate specific 
antigen (PSA) in the blood. Patients with increased PSA generally undergo ultrasound 
guided biopsies for histological diagnosis. The Gleason grading system provides 
visual markers for estimation of prognosis and the selection of therapy [5-7]. Today, 
the Gleason grade and serum level of PSA, combined with more sophisticated 
methods such as magnetic resonance imaging (MRI) and computer tomography (CT), 
provide the best available estimate of tumor stage and aggressiveness [8]. This 
information enables the oncologist to assess whether the patient may be cured or not.  
Radical perineal prostatectomy and radiation therapy are preferred treatments for 
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prostate cancers localized within the prostate and adjacent tissues [9]. In these cases 
the treatment aims at a complete cure. However, at the time of presentation, more than 
50% of patients either have locally advanced disease or secondary lesions [10]. 
Although surgical resection of isolated metastases is beneficial for some patients, the 
overall efficacy of surgery is limited in such cases [11, 12]. Fortunately, and due to 
the fact that the level of testosterone is of crucial importance for prostate cell division 
and differentiation [13-16], approximately 80% of prostate cancers are initially 
sensitive to androgen hormone stimulation. Consequently, anti-androgens, like 
Casodex® or Soladex®  [17, 18] can be used with good effect in this patient category. 
With time most prostate cancers become less androgen dependent, and will thus 
acquire resistance to anti-androgen therapy. These tumors are commonly called 
hormone refractory prostate cancers (HRPCA) [19]. However, cell clones that are 
hormone insensitive may respond to other therapeutic modalities such as 
chemotherapy [20-22], immunotherapy [23], or growth factor inhibitors [24, 25].  
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Future prospects  
In general, today’s anti-cancer drugs are designed to inhibit the uncontrolled 
proliferation of tumor cells, even though some new drugs may also affect other 
aspects of malignant behaviour, e.g. by preventing formation of new blood vessels 
(neoangiogenesis). However, carcinogenesis and tumor progression are associated 
with abnormalities in various aspects of cell behavior, not only an increased 
proliferation rate [26]. There is also a reduced tendency to undergo apoptosis [27], 
altered cell adhesion  [28, 29] and augmented motility [30, 31]. In recent years many 
investigators have focused on the development of drugs with the potential to influence 
the malignant phenotype. Clearly, our understanding of molecular and cellular 
processes behind such mechanisms has increased substantially through the past 
decades. This knowledge has led to an extensive search for treatment directed against 
the cancer cells’ ability to infiltrate surrounding tissue and form metastases. A 
malignant epithelial cell population is primarily characterized by its ability to 
penetrate anatomical barriers such as basal laminas (BL) and interstitial stroma. These 
events are thought to be induced by the production of proteolytic enzymes secreted by 
the cancer cells or by adjacent tissue [32-34]. Extracellular proteolysis occurs widely 
in nature and serves many different purposes. In multicellular organisms proteases are 
involved in cell growth and tissue differentiation. Besides these important processes, 
such enzymes have a role in blood coagulation, blood pressure regulation  [35-37] and 
in the digestion of food. However, it is well-documented that various proteases 
participate in invasive growth of numerous cells, especially the metalloproteinases 
and serine proteases [38]. Among them plasminogen activator (PA) has attracted most 
interest (Figure 1). A number of investigators have demonstrated a strong correlation 
between increased PA-activity and the capacity of malignant tumors to invade 
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surrounding tissue [39-42]. The production of PA may become a central target for 
novel drugs with inhibitory effect on tumor cell invasion, and in the development of 
diagnostic methods that can identify aggressive variants. 
Different cancers show different patterns of metastasis. Bone, as well as lung and 
liver, are the most frequent metastatic target sites for metastases from primaries of the 
breast and prostate, although the precise molecular mechanisms underlying such 
preferences of tissues need to be further elucidated. Both homotypic and heterotypic 
cell-to-cell adhesion interactions, in addition to cell-matrix interplays, are thought to 
participate in the determination of organ-specific tumor localization. It appears that 
bone matrix possesses unique biological features which permit circulating prostate 
cancer cells to home, survive and proliferate  [43] . Mechanisms involved in 
malignant cell adhesion have recently been reviewed [44]. Drugs affecting the cancer 
cells’ ability to adhere to various tissue components may be of therapeutic 
importance, with possibilities to block the formation of metastases. Moreover, 
collaboration has been demonstrated between the receptor for urokinase (uPAR) and 
cell adhesion molecules such as integrins. Such interplay participates in 
reorganization of the cytoskeleton, e.g. by stimulating the production of membrane 
wrinkles and the creation of lamellopodia and uropodia, all of great importance in cell 
adhesion and cell motility [45-48]. Drugs modifying the expression or functional 
properties of cell adhesion molecules may conceivably be useful suppressors of the 
metastatic process.  
 10
 
Figure1. The proteolytic efficacy of uPA relies on its interactions with factors such as 
plasminogen activator inhibitor-1 (PAI-1), the receptor binding uPA (uPAR), and 
inactive metalloproteinases. Recent studies have implicated a role for uPAR in 
cytoskeletal rearrangement, possibly leading to altered cell migration. 
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Tyrosine phosphorylation in malignant cell behavior 
Regulatory principles 
Protein tyrosine kinases (TKs) are enzymes that catalyze the transfer of phosphate 
groups from adenosine triphosphate (ATP) to tyrosine residues on specific protein 
substrates. Human cells contain more than 500 TKs [49], which play an important 
role in diverse cellular regulatory processes [50-53]. They work as mediators of 
signals leading to cell proliferation, differentiation, and migration, as well as to cell 
death [54]. There are two main classes of TKs, receptor bound and non-receptor 
bound.  
Growth factor receptors, which are transmembrane molecules composed of an 
extracellular ligand site, a transmembrane adaptor and an intracellular domain with 
enzymatic activity, are activated by binding an extracellular signal molecule, such as a 
growth factor (Figure 2). For instance, the EGFR family consists of four related 
transmembrane receptors that are involved in regulation of cellular growth and 
differentiation. In the absence of a ligand, a receptor TK is unphosphorylated and 
monomeric. When a ligand binds to the extracellular domain of the receptor, an 
oligomerization of receptors takes place, which in turn leads to phosphorylation of  
regulatory tyrosines   [55-57]. Multiple cytoplasmic signalling pathways, including 
the rat sarcomas (RAS) mitogen-activated protein kinase pathways, the 
phosphoinositol 3-kinase (PI3K) pathway and the protein kinase C pathway may then 
be activated. TK signaling is terminated through the action of tyrosine phosphatases 
or by other inhibitory intracellular molecules. 
The non-receptor TKs are cytoplasmic proteins, exhibiting considerable structural 
variability. They are for instance known as mediators in Src homology-2 (SH2) and 
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Src homology-3 (SH3) signaling pathways, and are maintained inactive by 
intracellular inhibitor proteins. They are activated e.g. when these inhibitors are 
dissociated from the enzyme [58]. 
 13
 
 
Figure2. Structure (a) and activation (b) of a typical tyrosine kinase receptor, the 
receptor binding epidermal growth factor (EGF). These receptors have one 
transmembrane segment. The extracellular portion of the receptor binds the ligand 
(EGF in this case). Inside the cell, a portion of the receptor has tyrosine kinase 
activity. The remainder of the receptor contains a series of tyrosine residues that are 
substrates for the tyrosine kinase. The activation of receptor tyrosine kinases starts 
with the binding of a messenger, causing receptor aggregation or clustering. Once the 
receptors aggregate, they cross-phosphorylate each other at a number of tyrosine 
amino acid residues (c). The formation of tyrosine phosphate (Tyr-P) residues on the 
receptor creates binding sites for cytosolic SH2 domains. 
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 Dysfunctions of TKs 
Enhanced expression of EGFR or its ligands such as EGF and transforming growth 
factor (TGF) can increase signaling via receptor-mediated pathways that may lead to 
excessive proliferation and cellular transformation. Several studies have shown that 
EGF binding to EGFR on tumor cells blocks apoptosis, and consequently promotes 
tumor growth and viability. Moreover, EGFR and its ligands have an important role in 
regulating angiogenesis [59-62]. Recent studies have demonstrated that TKs are 
dysregulated in cancer cells in several ways. Dysfunctions in growth factor signal 
cascades probably represent a main characteristic in the progression of malignant cell 
behavior [63-66].  
Normally, the level of intracellular protein phosphorylation is tightly controlled. 
However, in cancers, various TK dysregulations occur (table 1), such as uncontrolled 
expression of TK-receptors or their ligands [67]. An abnormality frequently seen is 
the fusion of TK-receptors with partner proteins, resulting in constitutive 
oligomerization in the absence of ligands. In this way autophosphorylation is 
promoted, resulting in uncontrolled activation of growth responses [68-71]. Another 
important mechanism in irregular activation of TKs involves mutations that disrupt 
the autoregulation of the kinase [72], Finally, increased TK activity may be due to a 
decrease of factors that limit TK activity, such as tyrosine phosphatases or other TK 
inhibitory proteins [73]. The network of regulatory pathways involving TKs is 
exceedingly complex, and its ramifications are not yet known in great detail. 
However, it seems beyond doubt that fundamental cellular processes, such as growth, 
survival, differentiation and motility, are largely determined by the phosphorylation 
status of key control proteins, and that these signal systems may be extensively 
interwoven. Thus, it is to be expected that many of the processes characteristic of the 
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malignant phenotype may be modified by inhibition of various TKs, and that 
meticulously selected tyrosine kinase inhibitors (TKIs) therefore may have a role to 
play as anti-cancer drugs. 
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Table1. Examples of dysregulated tyrosine kinases in various cancer types. 
            [74-76] 
       
     Tyrosine kinase                        Mechanism                             Examples 
EGFR (ErbB1)  Mutation (EGFR-vIII)  Gliomas  
   Mutations in TK-domain  Non-small cell lung cancer  
   Over-expression or 
growth factor mediated 
activation 
Head- and neck, lung-, 
breast-, prostate- and 
colorectal cancer 
HER2 (ErbB2)  Over-expression (e.g. 
amplification of the gene) 
Breast-, ovary- and lung 
cancer 
c-Kit (cellular homolog of 
the feline sarcoma viral 
oncogene) 
Mutation (constitutive TK 
activity) 
Gastrointestinal stromal 
tumors (GIST)  
PDGFR (platelet-derived 
growth factor receptor) 
Mutations Fibrosarcoma, chronic 
myelomocytic leukaemia   
         
Non-receptor tyrosine 
kinases  
      
Bcr-Abl (Breakpoint 
cluster region-Abelson) 
Mutation (translocation)  Chronic myeloid  leukemia  
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Inhibitory strategies
TK activity may be inhibited by antibodies against TKRs or their ligands, preventing 
the binding of ligands to the receptors or restraining the dimerization of the latter [77, 
78]. However, the most obvious candidate drugs are those which consist of small 
molecules capable of traversing the cytoplasmic membrane and binding to the 
intracellular domain of the TK-receptor, thereby blocking its interaction with ATP or 
protein substrates [79, 80].  
Recently, a number of small molecular TKIs have become available, and some are 
already used in the treatment of human tumors. The most successful so far are 
Gleevec® (imatinib) [81] and Iressa® (ZD1839) [82-84], which are often given in 
combination with cytostatic drugs [85].  
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Objectives 
So far, the rationale behind the use of TKIs in cancer chemotherapy is the idea that 
these substances will inhibit excessive cell proliferation. However, an effective 
inhibition of cell division will inevitably also cause damage to many normal cell 
populations. It is an interesting possibility that in malignant tumors the disrupted 
proliferation control and the unchecked invasive behavior may depend on similar 
mechanisms and related regulatory key points. Anti-cancer drugs specifically 
designed to counteract the tumor cells’ invasive behavior could be less toxic with 
fewer side effects, since this phenotype, characterized by cell migration across tissue 
and organ limits, is only shown by very few normal cell types.  
The main objective of the work carried out in preparation of this PhD thesis was to 
explore the possibility that TKI treatment may be used to modify cancer specific 
behavior in an in vitro model. In the included papers we focused on the production of 
proteolytic enzymes and the expression of cell adhesion molecules in cultured 
prostatic cancer cells, examining the possibility that these functions may be 
susceptible to TKI treatment. Even though the cell culture model used in these studies 
is highly artificial, we believe that the results obtained through such experiments may 
be useful in the search for new pharmaceutical principles in the treatment of human 
cancer. 
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General materials and main methods 
(Details in enclosed publications) 
Cell lines 
The human prostatic carcinoma cell lines PC-3  [86] and DU-145  [87] and LNCaP  
[88] were obtained from the American Type Culture Collection (ATCC). The cells 
were maintained as monolayers in 75 cm2 tissue culture flasks in Ham’s F-12 medium 
supplemented with 10% foetal bovine serum, l-glutamine, penicillin and 
streptomycin. Cells were grown at 37° C in a humidified environment containing 5% 
CO2. During the experimental period, the cells were repeatedly tested and found to be 
free of mycoplasma. 
TKIs 
Genistein and the tyrphostins AG -1478, AG-490 and AG-1296 were obtained from 
Calbiochem, San Diego, California. Genistein, which is a broad range TKI, inhibits 
substrate phosphorylation by EGFR and p60 kinases [89]. The tyrphostins constitute a 
group of compounds which are inhibitors of various tyrosine kinases, thus, AG 490 is 
able to selectively inhibit JAK-2 [90], whereas AG 1296 is a selective inhibitor of 
PDGF-receptor kinase [91]. Tyrphostin AG- 1478 is reported to be a highly specific 
inhibitor of EGF induced tyrosine phosphorylation [92]. 
Cell toxicity measurement 
Effects on cell proliferation caused by the TKIs were examined by a standard (3-(4.5-
Dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide) (MTT) assay. Oxidation of 
MTT takes place only when mitochondrial reductase enzymes are active, leading to 
conversion of MTT to a purple formazan, and the amount of color thus produced is 
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directly related to the number of viable cells. Induction of apoptosis was examined by 
a caspase colorimetric assay, capable of detecting three different enzymes (caspase 1, 
3 and 8). Cell viability was analysed by flow cytometry using annexin/propidium 
iodide and APOPTEST-FITC-kit. Non-cytotoxic doses of TKIs were chosen for the 
rest of this investigation. 
 
Determination of cell invasion 
Falcon invasion chambers were used to determine cell invasion (figure 3). They 
consists of a 24-well plate with cylindrical cell culture inserts, whose lower opening is 
closed by an 8 μm pore size polyethylene terephthalate (PET) membrane covered 
with a thin layer of a protein mixture (Matrigel®) (Becton &Dickinson Labware, 
Sweden). The protein layer occludes the pores, thus preventing non-invasive cells 
from passing through the membrane. In contrast, invasive cells are capable of 
penetrating through the membrane pores, presumably by a process involving 
proteolytic degradation of the matrix. 
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Figure3. Falcon invasion chambers. The culture insert is occluded with a porous 
plastic (PET) membrane. The pores are covered with a thin layer of a protein mixture 
(Matrigel®) (A). Invading cells must destroy the protein layer before entering the 
attractive cell environment (B), and such cells will thus become localized on the lower 
side of the PET membrane (C), directly in contact with the medium of the main well. 
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Quantification of proteolytic enzymes and their receptors 
The activity of uPA in the culture medium as well as in cell homogenates was 
measured with a colorimetric substrate, and an enzyme-linked immunosorbent assay 
(ELISA) was used to assess the amount of enzyme protein as well as that of enzyme 
receptors. Another colorimetric substrate was used to measure MMP activity in cell 
homogenate. Several MMPs are able to cleave the substrate used, among others 
MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13 and MMP-17.  
Immunocytochemistry using an antibody against uPAR (Dia-Service, Sweden) was 
used to examine the receptor distribution in cells grown in Falcon invasion chambers. 
Human Focus microarrays (Affymetrix, Santa Clara, CA) were used to examine the 
overall transcription pattern of genes related to proteolysis. More detailed mRNA 
quantification was done with real time reverse transcriptase polymerase chain reaction 
(qRT-PCR). 
Cell adhesion measurement 
Adhesion to extracellular matrix was assayed by seeding fluorescence labelled cells 
on culture substrates covered with collagen type I, collagen type IV, fibronectin, 
laminin or vitronectin, followed by measurement of the fluorescence intensity after 
removal of non-adherent cells. 
The expression levels of integrin β1, α2, α3 and α5 subunits were assessed by flow 
cytometry of cells labelled with monoclonal murine antibodies. Human Focus 
microarrays (Affymetrix, Santa Clara, CA) were used to measure the levels of various 
adhesion molecules’ mRNA transcripts. 
 23
Summary of results
The thesis represents a systematic investigation of effects caused by treatment of 
prostate adenocarcinoma cells PC-3 and DU-145 with TKIs. In order to assess the 
toxic effects caused by the TKIs, various parameters such as induction of apoptosis, 
altered proliferation rate and reduced cell viability were measured. After an initial 
mapping of the TKIs’ cellular toxicity, the dose range was chosen so as to cause 
minimal damage to the cells. Thus, the drug treatment was non-toxic under the 
conditions used, except that genistein at the highest dose produced 10-15% decreased 
viability in both cell lines. 
  
Cell invasion (Paper II) 
Cell invasion as measured in an artificial BL model was increased by the addition of 
plasminogen to the culture medium. This plasminogen effect was decreased by at 
least 60 % in both cell lines when α-2 anti-plasmin was added to the medium. The 
increased invasion induced by plasminogen was also counteracted by treatment with 
either of the two TKIs genistein or AG-1478. In the absence of plasminogen TKI had 
little or no effect on the invasive capability of the cells. Moreover, external uPA 
added to the medium failed to regenerate the decreased cell invasion caused by TKIs.  
 
Production of proteolytic enzymes (Paper I and IV) 
Genistein treatment led to a dramatic reduction of uPA secretion in both cell lines, 
and a decreased expression was also demonstrated at the mRNA level. AG-1478 
inhibited the production of uPA in PC-3, whereas DU-145 showed a slight increase of 
uPA secretion. However, no significant alteration in uPA mRNA expression was 
found after AG-1478 treatment. Moreover, treatment with TKIs led to approximately 
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a 50 % reduction of MMPs in PC-3 and DU-145 cell lysates (Paper II). However, 
only minor alterations of MMP mRNA were demonstrated. 
 
Expression of cell-membrane associated molecules (Paper III and Paper V) 
By immunohistochemistry an intense uPAR immunostaining was shown in actively 
invading cells, particularly at the leading edge membrane. Moreover, our results point 
out interesting differences in treatment response between the two cell lines, inasmuch 
as both TKIs induced a decreased level of uPAR proteins in DU-145, while PC-3 
remained unaffected. Thus, TKI treatment was actually leading to an equalization of 
uPAR expression in the to cell lines. A reduction of uPAR gene expression was found 
in TKI treated DU-145 cells, while no significant change was demonstrated in PC-3 
(Paper IV).  
Examination of the cells’ ability to adhere to various ECM proteins revealed that TKI 
treatment led to an overall reduced adhesion to the proteins tested. This observation 
was supported by the demonstration of a reduced expression of various integrin 
subunits in cells treated with TKIs, a pattern which was partly verified at the mRNA 
level (Paper IV). 
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General discussion  
In vitro models- limitations and possibilities  
Although malignant tumors of the prostate are a major contributor to cancer related 
morbidity and death in Western countries, the study of prostate carcinogenesis and 
tumor progression has not improved the treatment of this common disease to any 
degree. Partly this might be explained by a lack of representative in vitro models. So 
far, the limited number of available prostate cancer models, compared to the number 
for other neoplasms, is conspicuous. For a long time, only three cell lines, namely PC-
3, DU-145 and LNCaP, were routinely used to study the biology of prostate cancer in 
vitro. This situation may be explained by the low success rate, which actually is in the 
1% range, in efforts to establish cell lines from prostatic tumor tissue. Currently, no 
more than 10 prostate cancer cell lines are available worldwide, and many of them do 
not reproduce typical features of prostatic epithelium, such as the expression of 
androgen receptors and/or secretion of prostate specific antigen (PSA). Moreover, 
several of these cell lines only grow in vivo as xenografts [93], and their usefulness is 
therefore limited.  
One distinct advantage with the use of cell lines is their ability to proliferate at 
constant pace through many passages, and therefore to give possibilities for long 
series of experiments without concern about shortage of tissue. However, the critical 
issue regarding the use of established cell lines is how representative they are of the 
corresponding cell type within the organism. Without doubt, a weak point in the use 
of simple cell culture systems is the fact that they fail to address the important and 
complex interaction between diferent cell types within a tumor. For example, in most 
cancer tissues, the interactions between malignant cells and their surrounding stroma 
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is of great importance. Thus, carcinoma cells seem to induce the stromal component 
to produce proteolytic enzymes, which contribute to the invasive capability of the 
malignant cells. This is in turn believed to be triggered by the release of chemical 
factors produced by the cancer cells, probably leading to increased stromal expression 
of cytokines and/or growth factors [94, 95]. Thus, proteolytic enzymes are often seen 
localized in the interface between the tumor cells and the stroma, while no such 
activity appears in the inner part of the tumor [96]. Hopefully, the development of in 
vitro co-culture models of epithelial and stromal cells may produce suitable tools to 
explore this kind of interaction.  
Despite the shortcomings of cell culture models, their use in cancer research has not 
decreased. It is well-documented that we can learn much about dysregulated cellular 
functions from studies of living cultured cells. Clearly, the behaviour of single cells in 
an organism is continuously adjusted according to the messages received as part of an 
extensive communication with the rest of the body. Yet established cell lines will 
retain several distinctive traits from the cells of origin. However, the complexity of 
multicellular organisms represents in itself a problem for the demonstration of direct 
cause-and-effect relationships. This has led to the need of simpler experimental 
systems, in which single factors can be more easily manipulated. The usefulness of 
cell culture studies must therefore be evaluated in such a context. Moreover, cell lines 
can be established from tumor tissue obtained from different metastatic localizations, 
giving the investigator the opportunities to explore factors favouring the spread of 
cancer and the tendency to metastasize to a particular organ. For instance, PC-3 cells, 
which have been isolated from a skeletal metastasis, appear to differ in a numerous of 
ways, e.g. regarding the production of proteolytic enzymes and their receptors and 
inhibitors, from DU-145 cells, which originate from a metastatic brain lesion. Not 
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surprisingly, the effects of TKI treatment were not identical in the two cell lines. The 
differences between androgen- independent and androgen-dependent metastatic 
lesions from prostate primaries are even more conspicuous. For instance, PC-3 and 
DU-145, both androgen-independent cell lines, exhibited higher levels of EGFR 
expression and autocrine induced tyrosine phosphorylation than normal prostatic 
epithelial cells or the androgen-responsive prostate cancer cell line LNCaP [97]. 
Moreover, an aberrant expression of EGFR or its ligand TGF have been demonstrated 
with strikingly high frequency in aggressive variants of prostate cancer, thus implying 
the presence of feedback loop for the hormone-independent growth [98]. The 
demonstration of such phenomena has guided investigators’ attention to a possible 
therapeutic potential for the TKI genistein, and its effects on cultured cells have been 
reviewed thoroughly. Together, these results suggest that regulators of the cell cycle 
may represent a potential molecular target for this soy isoflavone [99, 100]. 
Since the occurrence of prostatic intra-epithelial neoplasia and carcinoma in situ are 
associated with progression towards an invasive phenotype, the establishment of cell 
lines from early stages will carry important prospects for future research. However, 
today such possibilities appear far from realistic, since the establishment of cell 
cultures from those tissues seems difficult. More realistic is the development of co-
culture systems, providing the ability to observe prostate cancer cells in interaction 
with bone cells, which may provide insight into the mechanisms underlying prostate 
cancers’ tendency to spread to bone.  
Cancer specific treatment 
Cancer is commonly understood to be the result of dysregulation of cell growth, and 
anti-cancer drugs have mainly been sought among chemical substances directly 
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inhibiting the cell-cycle or interfering with signal systems promoting cell 
proliferation. The development of growth factor receptor inhibitors has recently 
become a central field of research. However, despite the development of several 
chemicals with such properties, usually TKIs, the presently available drugs serve as 
second or third line therapy rather than constituting a primary choice. 
Various TKIs have been used in clinical trials, and their effects have been thoroughly 
reviewed. In summary, treatment with TKIs has shown positive effects in patients 
with non-small cell lung cancer, breast cancer and in patients with leukemia, 
especially when given in combination with conventional cytostatics or radiation 
therapy [101-103]. Not surprisingly, the best results are obtained when the TKs are 
mutated and permanently active, for instance in chronic myeloid leukaemia. There are 
also promising results with TKIs in the treatment of HER-2-positive breast cancers 
[101]. Moreover, TKIs have been shown to counteract other aspects of malignant 
disease, such as neoangiogenesis [104]. 
Despite extensive research into the biology of prostate cancer, which has led to ever 
increasing knowledge about its nature, a major breakthrough in the treatment of the 
disease has not yet appeared. Advances in clinical treatment of patients have up to 
now been achieved by optimization of available conventional therapies which have 
been used for many years. Considering the number of deaths caused by prostate 
cancer, it is obvious that today’s treatment is inadequate, and that the development of 
more efficient drugs is greatly needed. Hopefully, the increased knowledge about 
malignant epithelial cells’ behaviour will open doors for new treatment strategies 
against the cancer’s primary characteristic, namely its ability to invade into 
neighbouring tissue and secondarily its ability to form distant metastasis. A therapy 
effectively preventing prostate cancer spread would undoubtedly be a revolution in 
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the treatment of HRPCs. A number of investigators have suggested that TKIs have the 
potential to modulate the invasive capacity of human cancer cells, especially in cases 
with dysregulated growth factor receptor pathways [105, 106]. Our own results, 
achieved by the study of in vitro invasion, support this view by demonstrating that the 
invasive property of prostatic cancer cells can be modulated by TKIs. Interestingly, 
the PC-3 cell line’s invasive capacity is influenced much more by TKIs than that of 
DU-145. Moreover, TKs appear to be especially effective inhibitors of over-expressed 
proteins, for example uPA in PC-3 cells. On the other hand, uPAR is more than twice 
as much expressed in DU-145 than PC-3 cells, and for this protein the DU-145 cell 
line is most readily affected by TKIs. These observations suggest that the expression 
of uPA and its receptor are activated through common signalling pathways induced by 
growth factors. In addition, our results indicate that the inhibition of extracellular 
proteolysis and of invasive growth may be achieved at substantially lower doses of 
TKIs than those needed for reduction of the tumor growth rate, which suggests that 
TKIs may be specifically designed to counteract the cancer cells’ ability to destroy 
surrounding tissues and to form metastases. 
A huge challenge in the search for drugs directed against prostate cancer invasion is to 
understand the complex interplay between the various mechanisms involved in cell 
migration, how these mechanisms are regulated, and how they may be modified. For 
instance, in order to metastasise to bone, prostate cancer cells must both detach from 
the primary tumor site and attach to bone matrix, whereupon they must survive and 
continue to proliferate and extend into the available space in the new environment. 
This illustrates that the process of invasion and metastasis consists of repeated 
detachment and attachment, thereby pointing out a central role for adhesion molecules 
as contributors to the invasive phenotype. Thus, loss of E-cadherin has been shown to 
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corrrelate with the invasive capacity of several tumors [107], while it is also widely 
held that prostate carcinoma cells depend on increased levels of integrins in order to 
attach to bone [108]. Drugs with suppressive effects on integrins, while stimulating 
the production of cadherins, may therefore play a role in invasion-inhibitory therapy. 
The results as shown in paper IV and V suggest that TKIs may play such a role. 
 
Further development 
Forthcoming studies on clinical handling of prostate cancer will without doubt focus 
on the identification of aggressive cases with an increased risk for progressive disease 
and formation of metastases. Based on such information patients will be selected for 
an individualized therapy, and unnecessary therapy can be avoided in many cases. 
The identification of suitable therapy will mainly be performed by evaluation of 
biopsies. This field has been reviewed several times, for example by Huges and 
collaborators [109]. One observation that could be informative regarding the 
identification of aggressive cases, is the observed over-expression of insulin-like 
growth factor binding protein 2 (IGBFB2) in malignant prostate epithelium [110]. 
For future development of new therapy, it should be kept in mind that the biological 
machinery is fundamentally the same in normal and transformed cells. This means 
that conventional anti-cancer drugs, which are essentially anti-proliferation drugs, will 
inevitably produce deleterious effects also in actively proliferating normal cell 
populations. Thus the risk of unwanted side effects is usually the factor limiting the 
extent of the treatment. TKIs which have been specially designed and selected to 
suppress various aspects of the cells’ invasive behaviour, might be expected to show 
less general toxicity than ordinary cytostatics, because of their relative specificity for 
malignant cells. At the present time, available TKIs are not the result of a systematic 
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search in this direction, and therefore the major challenge is still to find new drugs 
with specific anti-tumour effects and minimal general toxicity.  
There is abundant evidence that the PA-system, with the key component uPA, its cell 
surface receptor uPAR and their inhibitors (PAIs), plays a key role in tumour invasion 
and metastasis. Thus, the PA-system seems well suited as a therapeutic target for 
patients with solid malignant tumours. However, this system provides proteolytic 
activity in many biological processes involving tissue remodelling, wound healing, 
ovulation and angiogenesis [111]. Activation of the PA-system is initiated by the 
release of PAs from specific cells in response to external signals, which via 
plasminogen results in a broad of spectrum protease activity. Because of the high 
concentration of plasminogen in virtually all tissues, altered occurrence of PAs may 
produce undesirable effects. For instance it is reasonable to assume that immune-
response cells may be affected. This problem must be further investigated, 
preferentially using relevant animal models to explore and validate possible side-
effects caused by drugs with the ability to inhibit the PA system. However, similar 
dilemmas are generally raised in most systemic treatment strategies. Targeted drug 
delivery supposes effective, precise and safe distribution of drugs, producing less 
systemic adverse effects. The controlled delivery of drugs is still a great challenge, 
and the success of TKIs affecting the PA-system may probably depend largely on 
improving their pharmacokinetics in terms of plasma stability and precise cellular 
uptake. Strategies for successful systemic delivery of PA-influencing TKIs may 
therefore be important in the future. 
It is well known that genistein treatment of cultured cells may cause inhibition of cell 
proliferation and induce apoptosis [100]. However, when we measured caspase-
enzymes (Paper I)) in TKI-treated PC-3 and DU-145 as an indication of programmed 
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cell death, no effect was demonstrated even at doses which produced a dramatic 
reduction of the cells’ invasive capacity (Paper II) . This supports the notion that the 
observed effects, e.g. the reduced production of uPA, are not secondary to non-
specific cytotoxicity. In clinical trials, the drugs still seem to be well-tolerated with 
fewer side effects than conventional cancer therapy. The most frequent side effects 
reported are a mild skin rash and brief diarrhea [112]. However, if new substances are 
systematically sought with the invasion-aspect in mind, one may hope to see drugs 
which can achieve good pharmaceutical effect at lower dosage, and with reduced risk 
of side effects. Targeted invasion-inhibitory therapy may therefore have the potential 
to reduce some of the problems presently seen in the field of cancer chemotherapy. 
The high rate of mutations in many cancer cells creates an additional problem which 
must be considered, namely the ability of cancer cells to acquire drug resistance. As 
TKIs gradually have been introduced in cancer therapy, this has become a great 
challenge [113]. 
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Conclusion 
The results presented in this thesis demonstrate that two TKIs, genistein and 
tyrphostin AG-1478, in an in vitro model system influenced the expression of several 
proteins thought to play important roles in cancer invasion and metastasis. Moreover, 
the observations highlight the heterogeneity present in different cell lines and surely 
also can be transferred to the in vivo situation. A challenge for the future will be to 
further analyse the frequency of, and mechanisms behind, dysregulated TKs in 
different human tumors, aiming at obtaining a tailored treatment. Thus the 
development of TKIs with effects which are better than or at least similar to those 
shown by genistein and AG-1478, with tolerable side effects, will be given high 
priority. Only through such efforts may TKI treatment be fully developed and find its 
place in the treatment of malignant tumors, solely or in combination with other drugs. 
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